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A B S T R A C T
A 76-year-old man presented with right critical limb ischemia. An angiography revealed right SFA
occlusion. Therefore, two paclitaxel-eluting stents (Zilver PTXs 6.0 mm  120 mm stents; Cook Medical,
Bloomington, Indiana) were placed, which promoted good blood ﬂow. Follow-up angiography at
6 months also showed no restenosis. However, 10 months later, the patient suddenly visited with acute-
onset pain in the right leg. Computed tomography showed the acute occlusion at the stented SFA.
Eventually, above-knee amputation was performed due to the poor general condition and progressive
limb ischemia. As the pathological ﬁnding, heterogeneous neointima formation at the stented site was
mainly found. Although neointimal layer consisting of smooth muscle cell (SMC) was partly observed,
necrotic tissue was evident in the remaining portion. At the necrotic tissue site, the majority of the
components of the material covered by the stent strut were ﬁbrin deposits. The ﬁndings of regenerative
endothelial cells were not observed at the luminal surface. Nuclei of medial SMCs were also lost between
the arterial media and the stent strut.
Late stent thrombosis after paclitaxel-eluting stenting for SFA lesion has not been sufﬁciently evaluated.
Here, we report a case of late stent thrombosis with a review including pathological ﬁndings.
<Learning objective: We reported that a 76-year-old man received paclitaxel-eluting stent for
femoropopliteal disease. Ten months later, stent thrombosis was occurred and above-knee amputation
was performed. As the pathological ﬁnding, heterogeneous neointima formation was mainly found and
the regenerative endothelial cells were not observed. Our report suggested that delayed healing and
uncovered strut caused by paclitaxel-exposure resulted in late stent thrombosis.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Superﬁcial femoral artery (SFA) lesions are generally long
segment stenoses with many chronic occlusions. Paclitaxel-eluting
stents show superiority to conventional procedures [1] and are
likely to provide higher therapeutic efﬁcacy. However, the
inﬂuence stent thrombosis after paclitaxel-eluting stenting for
SFA lesion has not been sufﬁciently evaluated. Here, we report a
case of major amputation due to late stent thrombosis after
implantation of a Zilver PTX, with a review including pathological
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A 76-year-old man presented with right critical limb ischemia.
An angiography revealed right superﬁcial artery (SFA) occlusion
(Fig. 1A), and endovascular therapy (EVT) was performed. Two
Zilver PTXs 6.0 mm  120 mm stents (Cook Medical, Bloomington,
Indiana) were placed to cover the whole lesion (Fig. 1B).
Postoperative imaging conﬁrmed good runoff of below-the-knee
arteries. The patient was discharged with prescriptions for the oral
anticoagulant (warfarin) for atrial ﬁbrillation and antiplatelet
agents of aspirin 100 mg and clopidogrel 75 mg.
Wound healing without restenosis was conﬁrmed at 3 and
6 months (Fig. 1C).
At 10 months after EVT, the patient visited our hospital with
sudden-onset pain in the right leg. Computed tomography showed
the acute occlusion from the origin to the distal part of the right
SFA (Fig. 1D). Above-knee amputation of the right limb was reserved.
Fig. 1.
Endovascular treatment for right superﬁcial femoral artery. (A) Pre-angiogram; (B) Final angiogram; (C) 6-months follow-up angiogram; (D) Acute-onset limb
ischemia at 10 months three-dimensional computed tomography for superﬁcial femoral artery (SFA) in acute occlusion. Occlusive lesion was found from
proximal SFA to distal SFA (green arrow).
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ischemia, and insufﬁcient narcotic pain control.
Pathological ﬁndings
The sample was ﬁxed in 10% buffered formalin and embedded
in parafﬁn. The parafﬁn block was stained with hematoxylin and
eosin. There were entirely necrotic tissues in the intimal side of the
stent struts, where almost no circumferential viable smooth
muscle cell (SMC) proliferation (Fig. 2A). The majority of the
components of the material covered by the stent strut were
necrotic tissue with ﬁbrin deposition. Furthermore, the ﬁndings of
regenerative endothelial cells were not observed at the luminal
surface. Nuclei of medial SMCs were also lost between the arterial
media and the stent strut, where necrotic tissues were observed. In
the stented regions, expansion of the stent strut forced the struts
contiguous to the medial layer, and remarkable loss of nuclei of
medial SMCs was obvious (Fig. 2B). The heterogeneous neointima
formation is shown (Fig. 2C). Although neointimal layer consisting
of SMCs was partly observed, necrotic tissue was evident in the
remaining portion. A low-power ﬁeld image showed SMC
proliferation including necrotic tissues near the superﬁcial layer
(Fig. 2D). The thrombotic occlusion site is shown in Fig. 2E. Massive
thrombus formation was observed mainly on the intimal side of
the uncovered stent struts. Tissue reaction at the stented site
including mainly ﬁbrin deposits, were partly observed around the
stent strut, but most of these portions were consisted of necrotictissue. The stent strut had squeezed the median smooth muscle
layer (Fig. 2F).
Discussion
The Zilver PTX stent incorporates a self-expanding nitinol stent
platform with a 3 mg/mm2 polymer-free coating of paclitaxel on
its outer surface. These stents deliver approximately 95% of the
total paclitaxel within 24 h after deployment, and the plasma
paclitaxel level becomes undetectable at 10 h. Local paclitaxel
levels in the artery wall may be sustained for 56 days [2].
Paclitaxel from the Zilver PTX is eliminated within 2 months and
the general duration of dual-antiplatelet therapy (DAPT; aspirin +
clopidogrel) is also 2 months. However, the case reported here was
interesting because stent thrombosis developed despite continua-
tion of DAPT due to placement of a drug-eluting coronary stent and
anticoagulant therapy for atrial ﬁbrillation (PT-INR = 3.13 at the
time of acute occlusion).
A coronary bare metal stent is almost fully covered by
neointima consisting of SMCs and extracellular matrix 1 month
after stent implantation. In contrast, in this study, the Zilver PTX
placement area showed heterogeneity, with regions with and
without neointimal proliferation (Fig. 2C). Heterogeneous neoin-
timal coverage after paclitaxel-eluting coronary stenting is already
reported. This pathological heterogeneity after Zilver PTX implan-
tation might be the possible effects of the types of techniques and
blood ﬂow on the local distribution of the drug [3]. The possible
Fig. 2.
Pathological ﬁndings (H&E stain). (A) Necrotic tissue site. Remarkable calciﬁcation of the medial wall (Mo¨nckeberg’scalcinosis) was evident in the 5 O’clock and
7–11 O’clock directions are shown. (B) Low-power ﬁeld indicated by arrow B; endothelialization was not observed at the luminal surface. Necrotic tissue with
ﬁbrin depositions was entirely observed. (C) Heterogeneous neointima site Necrotic tissues were observed in the 6–12 O’clock direction. In the other area,
neointimal layer was found. (D) Low-power ﬁeld indicated by arrow D. (E) Massive thrombus site Thrombi were extruding into the lumen and these thrombi were
attached to the stent strut in the 1–6 O’clock direction. (F) Low-power ﬁeld indicated by arrow F. Thrombus formation was observed on the surface of these
nectotic portions. Stent strut was surrounded by thrombotic components and necrotic tissues and it was attached by a very small number of smooth muscle cells.
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et al. reported angioscopy ﬁndings of a large red thrombus and an
uncovered stent strut in a patient with stent thrombosis 6 months
after placement of Zilver PTX [4]. An uncovered stent strut and
heterogeneity of healing have been shown to cause late stent
thrombosis in the coronary artery [6] and our pathologic ﬁndings
also indicated thrombi directly attached to an uncovered stent
strut and heterogeneity of healing. This suggests that these
ﬁndings may be risk factors for late stent thrombosis in cases with
SFA lesions.
Mechanism of late stent thrombosis after SFA stenting
remains unclear and the optimal medical therapy has not been
established. The efﬁcacy of DESs for SFA is likely to increase,
including additional indications for treatment of complex
lesions, but further investigation is needed to examine the
trade-off between the risk of stent thrombosis, which may
directly cause serious limb events, and the efﬁcacy of restenosis
inhibition.
Financial support
None.Conﬂict of interest
None declared.
References
[1] Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Snyder SA, O’Leary
EE, Tepe G, Scheinert D, Zeller T, Zilver PTX Investigators. Sustained safety and
effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year
follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am
Coll Cardiol 2013;61:2417–27.
[2] Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymer-free paclitaxel-coated
Zilver PTX Stents—evaluation of pharmacokinetics and comparative safety in
porcine arteries. J Vasc Interv Radiol 2011;22:603–10.
[3] Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F,
Minamiguchi H, Kotani J, Nagata S. Heterogeneous arterial healing in patients
following paclitaxel-eluting stent implantation: comparison with sirolimus-
eluting stents. JACC Cardiovasc Interv 2009;2:453–8.
[4] Ishihara T, Iida O, Awata M, Shiraki T, Nanto S, Uematsu M. Angioscopically
apparent large thrombus and uncovered stent struts 6 months after late stent
thrombosis of a paclitaxel-coated nitinol drug-eluting stent implanted in the
superﬁcial femoral artery. Cardiovasc Interv Ther 2014;29:82–5.
[5] Fukuda K, Higashimori A, Fujihara M, Yokoi Y. The breakage of a drug-eluting
stent delivery system leading to limb amputation. Cardiovasc Interv Ther
2014;29:60–4.
[6] Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani
R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage
as a marker of endothelialization. Circulation 2007;115:2435–41.
